Cannabis use prevalence, patterns, and reasons for use among patients with cancer and survivors in a state without legal cannabis access

McClure, Erin A.; Walters, Kyle J.; Tomko, Rachel L.; Dahne, Jennifer; Hill, Elizabeth G.; McRae‐Clark, Aimee L.

doi:10.1007/s00520-023-07881-6

Cited by 16 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although cannabis use did not show a direct relationship with individuals experiencing pain, it was associated with suggestive anxiety disorders. A recent US study reported that the most common reasons for cannabis use by cancer patients and survivors were difficulty sleeping (50%), pain (46%), and mood changes and stress, anxiety, or depression (45%) 48 . Interestingly in the cited study, patients reported also a symptom improvement for pain (57%), stress/anxiety/depression (64%), difficulty sleeping (64%), and loss of appetite (40%) 48 .…”

Section: Discussionmentioning

confidence: 98%

“…A recent US study reported that the most common reasons for cannabis use by cancer patients and survivors were difficulty sleeping (50%), pain (46%), and mood changes and stress, anxiety, or depression (45%) 48 . Interestingly in the cited study, patients reported also a symptom improvement for pain (57%), stress/anxiety/depression (64%), difficulty sleeping (64%), and loss of appetite (40%) 48 . Nevertheless, the recent guideline issued by the Multinational Association of Supportive Care in Cancer advises against using cannabinoids as an adjuvant analgesic for cancer pain, emphasizing the importance of carefully considering the potential risks of harm and adverse events 49 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Study of the relationship between psychoactive substance use and pain in cancer patients and cancer survivors: A French nationwide cross‐sectional study

Ragusa,

Pereira,

Balayssac

2024

Intl Journal of Cancer

View full text Add to dashboard Cite

Pain is a prevalent symptom among cancer patients and survivors. Psychoactive substance use (PSU) is associated with both the presence and severity of pain. However, little is known about this association in the context of cancer. The primary objective was to compare the prevalence of PSU and its relationship with pain during and after cancer. PSU was defined as the use of nonmedication substances (alcohol, tobacco, e‐cigarettes, cannabidiol, and cannabis), with frequency categorized as at least yearly, monthly, weekly, or daily. Secondary objectives aimed to explore the relationships between PSU and pain characteristics, health‐related quality of life, anxiety, depression, deprivation, and individual characteristics. Among the 1041 individuals included, pain prevalence was 44.7% (95% confidence interval [CI] 41.6%–47.8%). The overall prevalence of PSU at least monthly was 67.0% (95% CI 64.0%–69.8%). The proportions of chronic and neuropathic pains were higher for at least monthly use of cannabidiol compared to nonuse (70.0% vs. 39.3% and 55.7% vs. 28.1%, p < .001). In multivariate analysis, the monthly uses of tobacco and cannabidiol were higher in painful individuals than in nonpainful ones (odds ratio: 2.85 [95% CI 1.22–6.64] and 3.76 [95% CI 1.13–12.44], p < .05). From the point of view of the patient care, the study underscores the need for physicians to prioritize smoking cessation and pay attention to the use of cannabidiol during and after cancer.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Study of the relationship between psychoactive substance use and pain in cancer patients and cancer survivors: A French nationwide cross‐sectional study

Ragusa,

Pereira,

Balayssac

2024

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Data suggest that from 20% to more than 40% of adults with cancer report cannabis use. 7-12 A recent observational study of adults undergoing cancer treatment at a National Cancer Institute–designated cancer center (N = 267) showed that those who used cannabis, as compared with those who did not, experienced more severe cancer-related symptoms and perceived cannabis as less harmful. 7 Regarding modes of cannabis use, participants tended to rely on edibles (65%) or combusted cannabis (51%).…”

Section: Introductionmentioning

confidence: 99%

Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline

Braun,

Bohlke,

Abrams

et al. 2024

JCO

View full text Add to dashboard Cite

PURPOSE To guide clinicians, adults with cancer, caregivers, researchers, and oncology institutions on the medical use of cannabis and cannabinoids, including synthetic cannabinoids and herbal cannabis derivatives; single, purified cannabinoids; combinations of cannabis ingredients; and full-spectrum cannabis. METHODS A systematic literature review identified systematic reviews, randomized controlled trials (RCTs), and cohort studies on the efficacy and safety of cannabis and cannabinoids when used by adults with cancer. Outcomes of interest included antineoplastic effects, cancer treatment toxicity, symptoms, and quality of life. PubMed and the Cochrane Library were searched from database inception to January 27, 2023. ASCO convened an Expert Panel to review the evidence and formulate recommendations. RESULTS The evidence base consisted of 13 systematic reviews and five additional primary studies (four RCTs and one cohort study). The certainty of evidence for most outcomes was low or very low. RECOMMENDATIONS Cannabis and/or cannabinoid access and use by adults with cancer has outpaced the science supporting their clinical use. This guideline provides strategies for open, nonjudgmental communication between clinicians and adults with cancer about the use of cannabis and/or cannabinoids. Clinicians should recommend against using cannabis or cannabinoids as a cancer-directed treatment unless within the context of a clinical trial. Cannabis and/or cannabinoids may improve refractory, chemotherapy-induced nausea and vomiting when added to guideline-concordant antiemetic regimens. Whether cannabis and/or cannabinoids can improve other supportive care outcomes remains uncertain. This guideline also highlights the critical need for more cannabis and/or cannabinoid research. Additional information is available at www.asco.org/supportive-care-guidelines .

show abstract

“…Young adults often perceive cannabis as “natural” and less harmful than other substances; yet it can adversely affect brain function, particularly during the critical developmental stage of young adulthood ( Whiteley et al, 2021 ). Medical cannabis is currently legal in 38 states, four US territories, and the federal District of Columbia (DC); non-medical use is permitted in 23 states, three US territories, and DC ( McClure et al, 2023 , National Conference of State Legislatures, 2023 ). The trend in legalization has advanced faster than prospective research and public understanding of cannabis ( Hasin, 2018 , Hazle et al, 2022 , Orenstein and Glantz, 2020 , Vidot et al, 2014 ).…”

Section: Introductionmentioning

confidence: 99%

Perceptions, Attitudes, and Knowledge of Cannabis and its Use: A Qualitative Study among Herbal Heart Study Young Adult Cannabis Consumers in South Florida

Baral,

Morales,

Diggs

et al. 2024

Preventive Medicine Reports

View full text Add to dashboard Cite

Cannabis use prevalence, patterns, and reasons for use among patients with cancer and survivors in a state without legal cannabis access

Cited by 16 publications

References 39 publications

Study of the relationship between psychoactive substance use and pain in cancer patients and cancer survivors: A French nationwide cross‐sectional study

Study of the relationship between psychoactive substance use and pain in cancer patients and cancer survivors: A French nationwide cross‐sectional study

Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline

Perceptions, Attitudes, and Knowledge of Cannabis and its Use: A Qualitative Study among Herbal Heart Study Young Adult Cannabis Consumers in South Florida

Contact Info

Product

Resources

About